Kowa Drug Patent Portfolio
Kowa owns 2 orange book drugs protected by 16 US patents Given below is the list of Kowa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846744 | Pharmaceutical compositions of co-crystals of tramadol and coxibs | 03 Jun, 2031 | Active |
| US10238668 | Co-crystals of tramadol and coxibis | 19 Apr, 2030 | Active |
| US10245276 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US10548909 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US11478488 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US8598152 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US9012440 | Co-crystals of tramadol and coxibs | 19 Apr, 2030 | Active |
| US7022713 | Hyperlipemia therapeutic agent | 19 Aug, 2024 | Expired |
| US8557993 | Crystalline forms of pitavastatin calcium | 02 Aug, 2024 | Expired |
| US7022713 | Hyperlipemia therapeutic agent | 19 Feb, 2024 | Expired |
| US8557993 | Crystalline forms of pitavastatin calcium | 02 Feb, 2024 | Expired |
| US5856336 | Quinoline type mevalonolactones | 25 Jun, 2021 | Expired |
| US5856336 | Quinoline type mevalonolactones | 01 Jan, 2021 | Expired |
| US6465477 | Stable pharmaceutical composition | 20 Dec, 2016 | Expired |
| US5854259 | Quinoline type mevalonolactones | 29 Dec, 2015 | Expired |
| US5753675 | Quinoline analogs of mevalonolactone and derivatives thereof | 19 May, 2015 | Expired |
Latest Legal Activities on Kowa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kowa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US9012440 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10238668 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8598152 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US8846744 |
| Notice of Final Determination- Ineligible | 07 Jun, 2024 | US10548909 |
| Notice of Final Determination- Ineligible | 06 Jun, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10245276 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10548909 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US8846744 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US8598152 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US9012440 |
| Letter from FDA or Dept of Agriculture re PTE application | 03 Jan, 2024 | US10238668 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Jul, 2023 | US10548909 |
| Initial letter Re: PTE Application to regulating agency | 28 Feb, 2023 | US10238668 |
| Initial letter Re: PTE Application to regulating agency | 28 Feb, 2023 | US8598152 |
Kowa's Drug Patent Litigations
Kowa's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 18, 2015, against patent number US5856336. The petitioner Mylan Pharmaceuticals Inc., challenged the validity of this patent, with Nissan Chemical Industries, Ltd. as the respondent. Click below to track the latest information on how companies are challenging Kowa's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5856336 | July, 2015 |
Institution Denied
(04 Feb, 2016)
| Nissan Chemical Industries Ltd. et al. | Sawai USA, Inc. et al. |
| US5856336 | July, 2015 |
Terminated-Denied
(04 Feb, 2016)
| Nissan Chemical Industries Ltd. | Sawai USA, Inc. |
| US5856336 | April, 2015 |
Institution Denied
(20 Oct, 2015)
| Nissan Chemical Industries, Ltd. et al. | Mylan Pharmaceuticals Inc. |
| US5856336 | April, 2015 |
Terminated-Denied
(20 Oct, 2015)
| Nissan Chemical Industries, Ltd. | Mylan Pharmaceuticals Inc. |
Kowa's Family Patents
Kowa Drug List
Given below is the complete list of Kowa's drugs and the patents protecting them.
1. Livalo
Livalo is protected by 9 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7022713
(Pediatric)
| Hyperlipemia therapeutic agent |
19 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US8557993
(Pediatric)
| Crystalline forms of pitavastatin calcium |
02 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US7022713 | Hyperlipemia therapeutic agent |
19 Feb, 2024
(1 year, 10 months ago)
| Expired |
| US8557993 | Crystalline forms of pitavastatin calcium |
02 Feb, 2024
(1 year, 11 months ago)
| Expired |
| US5856336
(Pediatric)
| Quinoline type mevalonolactones |
25 Jun, 2021
(4 years ago)
| Expired |
| US5856336 | Quinoline type mevalonolactones |
01 Jan, 2021
(5 years ago)
| Expired |
| US6465477 | Stable pharmaceutical composition |
20 Dec, 2016
(9 years ago)
| Expired |
| US5854259 | Quinoline type mevalonolactones |
29 Dec, 2015
(10 years ago)
| Expired |
| US5753675 | Quinoline analogs of mevalonolactone and derivatives thereof |
19 May, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Livalo's drug page
2. Seglentis
Seglentis is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846744 | Pharmaceutical compositions of co-crystals of tramadol and coxibs |
03 Jun, 2031
(5 years from now)
| Active |
| US10238668 | Co-crystals of tramadol and coxibis |
19 Apr, 2030
(4 years from now)
| Active |
| US10245276 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US10548909 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US11478488 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US8598152 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
| US9012440 | Co-crystals of tramadol and coxibs |
19 Apr, 2030
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seglentis's drug page